Your browser is no longer supported. Please, upgrade your browser.
CWBR [NASD]
CohBar, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own1.10% Shs Outstand58.55M Perf Week-21.43%
Market Cap72.63M Forward P/E- EPS next Y-0.36 Insider Trans-1.36% Shs Float43.48M Perf Month-10.57%
Income-16.30M PEG- EPS next Q-0.07 Inst Own13.40% Short Float6.72% Perf Quarter-41.80%
Sales- P/S- EPS this Y-9.40% Inst Trans0.02% Short Ratio5.61 Perf Half Y1.85%
Book/sh0.32 P/B3.44 EPS next Y-33.30% ROA-91.50% Target Price- Perf Year-59.56%
Cash/sh0.32 P/C3.46 EPS next 5Y- ROE-127.80% 52W Range0.85 - 3.20 Perf YTD-17.91%
Dividend- P/FCF- EPS past 5Y-22.50% ROI- 52W High-65.62% Beta2.78
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low29.41% ATR0.11
Employees11 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)35.20 Volatility8.98% 8.18%
OptionableNo Debt/Eq0.03 EPS Q/Q7.00% Profit Margin- Rel Volume0.55 Prev Close1.17
ShortableYes LT Debt/Eq0.02 EarningsMay 17 AMC Payout- Avg Volume520.95K Price1.10
Recom2.00 SMA20-13.21% SMA50-18.91% SMA200-16.52% Volume286,590 Change-5.98%
Mar-15-21Initiated Aegis Capital Buy $6
May-03-21 09:00AM  
Apr-27-21 08:30AM  
Apr-22-21 09:56AM  
Apr-21-21 09:00AM  
Apr-14-21 09:00AM  
Mar-30-21 04:02PM  
02:45PM  
Mar-29-21 09:00AM  
Mar-16-21 04:05PM  
09:00AM  
Mar-12-21 09:00AM  
Mar-02-21 09:00AM  
Feb-25-21 09:00AM  
Feb-09-21 09:00AM  
Jan-20-21 09:00AM  
Jan-11-21 09:00AM  
Dec-09-20 09:00AM  
Nov-19-20 09:00AM  
Nov-16-20 04:01PM  
03:15PM  
Nov-09-20 03:30PM  
Nov-02-20 09:00AM  
07:35AM  
Oct-29-20 09:00AM  
Oct-27-20 09:00AM  
Oct-26-20 09:00AM  
Oct-15-20 04:05PM  
Oct-08-20 09:00AM  
Oct-05-20 09:00AM  
Sep-29-20 04:05PM  
Sep-10-20 04:05PM  
Sep-04-20 11:24AM  
Sep-03-20 08:45AM  
Aug-28-20 04:05PM  
Aug-26-20 08:30AM  
Aug-25-20 04:55PM  
Aug-24-20 09:00AM  
Aug-13-20 04:03PM  
Aug-05-20 09:00AM  
Jul-30-20 09:00AM  
Jul-07-20 09:00AM  
Jul-06-20 09:00AM  
Jun-30-20 09:00AM  
Jun-17-20 09:00AM  
Jun-02-20 09:00AM  
May-27-20 09:00AM  
May-14-20 04:02PM  
May-13-20 09:00AM  
May-05-20 09:00AM  
May-01-20 11:00AM  
Apr-30-20 09:00AM  
Apr-19-20 09:21AM  
Apr-14-20 08:30AM  
Mar-30-20 08:45AM  
Mar-12-20 04:02PM  
03:00PM  
08:30AM  
Mar-02-20 04:30PM  
Jan-28-20 09:00AM  
Jan-22-20 09:00AM  
Jan-08-20 09:00AM  
Dec-23-19 08:04PM  
Dec-16-19 09:00AM  
Nov-06-19 04:04PM  
Nov-05-19 09:00AM  
Oct-24-19 09:00AM  
Oct-23-19 08:45AM  
Oct-15-19 09:00AM  
Aug-07-19 04:05PM  
Jul-31-19 04:05PM  
Jun-10-19 09:00AM  
Jun-05-19 09:00AM  
May-29-19 09:00AM  
May-07-19 04:03PM  
03:00PM  
09:00AM  
Apr-26-19 03:35PM  
Apr-23-19 09:00AM  
Apr-22-19 09:00AM  
Mar-18-19 04:03PM  
Mar-04-19 09:00AM  
Feb-11-19 09:00AM  
Dec-10-18 04:05PM  
Nov-29-18 08:40AM  
Nov-26-18 09:00AM  
Nov-14-18 04:03PM  
Nov-08-18 09:00AM  
Nov-05-18 09:00AM  
Oct-31-18 09:00AM  
Oct-22-18 08:20AM  
Sep-25-18 09:00AM  
Aug-14-18 04:03PM  
Aug-02-18 01:09PM  
Jul-12-18 09:00AM  
Jun-27-18 04:05PM  
09:00AM  
Jun-25-18 12:08PM  
Jun-07-18 08:59AM  
Jun-06-18 09:45AM  
May-29-18 09:00AM  
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cundy Kenneth CChief Scientific OfficerFeb 16Option Exercise0.7310,0007,30020,000Feb 18 04:30 PM
Cundy Kenneth CChief Scientific OfficerFeb 16Sale1.9010,00019,00010,000Feb 18 04:30 PM
Petkevich MishaDirectorSep 03Buy1.0211,00011,220240,609Sep 04 09:00 AM
Petkevich MishaDirectorSep 02Buy1.006,0006,000229,609Sep 03 09:07 AM
Cundy Kenneth CChief Scientific OfficerAug 06Option Exercise0.7310,0007,30020,000Aug 10 04:13 PM
Cundy Kenneth CChief Scientific OfficerAug 06Sale1.9010,00019,00010,000Aug 10 04:13 PM